On January 8, 2026, the multinational biopharmaceutical giant AstraZeneca officially announced the appointment of a new Head of Investor Relations. This leadership transition is part of the company’s strategy to strengthen its executive team in preparation for its next phase of global growth.
Key personnel and transition timeline
-
New Appointee: Mr. Joris Silon will officially assume the role on March 1, 2026, based in Cambridge, UK.
-
Predecessor: Mr. Andy Barnett will conclude his four-year tenure leading the department and transition to a significant new role within the organization.
Expertise and professional background Joris Silon is a veteran leader who joined AstraZeneca in 2000. Prior to this appointment, he served as the Country President of AstraZeneca US—the company’s largest market—where he was credited with delivering substantial growth and business expansion. His career also spans various senior leadership positions across Asia and Europe.
Aradhana Sarin, Chief Financial Officer of AstraZeneca, expressed confidence that Joris Silon’s extensive international experience and deep understanding of the pharmaceutical landscape will be instrumental in managing the company’s engagement with the global financial community.
Source: https://view.news.eu.nasdaq.com/view?id=b59a6b8da06453fd501fc38aa4fbbf126&lang=en&src=listed